Evaluation of glycated hemoglobin and fetal hemoglobin-adjusted HbA1c measurements in infants

Suzuki, Shigeru; Koga, Masafumi; Niizeki, Noriyasu; Furuya, Akiko; Matsuo, Kumihiro; Tanahashi, Yusuke; Tsuchida, Etsushi; Nohara, Fumikatsu; Okamoto, Toshio; Nagaya, Ken; Azuma, Hiroshi

doi:10.1111/pedi.12013

Cited by 17 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The doses for these participants were converted into glibenclamide equivalents [16]. We omitted HbA 1c data for patients under 6 months of age as these values are not interpretable due to the persistence of fetal haemoglobin [17]. Focused efforts were made to collect medical records and detailed information from treating clinicians whenever possible, particularly regarding details of the attempted transition to SU therapy.…”

Section: Methodsmentioning

confidence: 99%

Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes

et al. 2015

View full text Add to dashboard Cite

Aims/hypothesis Individuals with heterozygous activating mutations of the KCNJ11 gene encoding a subunit of the ATP-sensitive potassium channel (KATP) can usually be treated with oral sulfonylurea (SU) pills in lieu of insulin injections. The aim of this study was to test our hypothesis that younger age at the time of initiation of SU therapy is correlated with lower required doses of SU therapy, shorter transition time and decreased likelihood of requiring additional diabetes medications. Methods We performed a retrospective cohort study using data on 58 individuals with neonatal diabetes due to KCNJ11mutations identified through the University of Chicago Monogenic Diabetes Registry (http://monogenicdiabetes.uchicago.edu/registry). We assessed the influence of age at initiation of SU therapy on treatment outcomes. Results HbA1c fell from an average of 8.5% (69 mmol/mol) before transition to 6.2% (44 mmol/mol) after SU therapy (p < 0.001). Age of initiation of SU correlated with the dose (mg kg−1 day−1) of SU required at follow-up (r = 0.80, p < 0.001). Similar associations were observed across mutation subtypes. Ten participants required additional glucose-lowering medications and all had initiated SU at age 13 years or older. No serious adverse events were reported. Conclusions/interpretation Earlier age at initiation of SU treatment is associated with improved response to SU therapy. Declining sensitivity to SU may be due to loss of beta cell mass over time in those treated with insulin. Our data support the need for early genetic diagnosis and appropriate personalised treatment in all cases of neonatal diabetes.

show abstract

Section: Methodsmentioning

confidence: 99%

Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes

et al. 2015

View full text Add to dashboard Cite

show abstract

“…We measured HbA1c by the HPLC method and the LA method in 26 healthy infants (0 to 8 mo old), calculated HbA1c values corrected by HbF [Adj-HbA1c (HPLC) and Adj-HbA1c (LA), respectively], measured GHb by the affinity method [GHb (Affinity)], and evaluated correlations between these values and plasma glucose and between these values and GA [72] . As a result, only GHb (Affinity) had a significant correlation with both plasma glucose and GA ( Figure 3A).…”

Section: Glycemic Control Indicators In Ndm: Hba1c and Gamentioning

confidence: 99%

“…It has been reported under various conditions that GA shows a low level when albumin metabolism is accelerated and shows a high level when albumin metabolism is suppressed [78] . While GA is a useful glycemic control indicator in , and PG or GA in 26 healthy infants were shown (modified from Ref [72] , with permission from Copyright Clearance Center Inc.). GA: Glycated albumin; PG: Plasma glucose; GHb: Glycated hemoglobin; HbF: Fetal hemoglobin.…”

Section: Suzuki S Et Al Glycemic Control Indicators In Ndmmentioning

confidence: 99%

Glycemic control indicators in patients with neonatal diabetes mellitus

Suzuki¹,

Koga²

2014

WJD

Self Cite

View full text Add to dashboard Cite

Neonatal diabetes mellitus (NDM) is a type of diabetes mellitus caused by genetic abnormality which develops in insulin dependent state within 6 mo after birth. HbA1c is widely used in clinical practice for diabetes mellitus as the gold standard glycemic control indicator; however, fetal hemoglobin (HbF) is the main hemoglobin in neonates and so HbA1c cannot be used as a glycemic control indicator in NDM. Glycated albumin (GA), another glycemic control indicator, is not affected by HbF. We reported that GA can be used as a glycemic control indicator in NDM. However, it was later found that because of increased metabolism of albumin, GA shows an apparently lower level in relation to plasma glucose in NDM; measures to solve this problem were needed. In this review, we outlined the most recent findings concerning glycemic control indicators in neonates or NDM.

show abstract

“…However, average HbF level was 1.28% of total Hb in the group with elevated fetal hemoglobin. Previous reports have revealed that a significant increase in HbF affects HbA1, especially concerning newborns, neonates and patients with hemoglobinophathies (13,14). Among these patients, relatively high HbF levels (even greater than 70% in newborns and to 5% in patients with hemoglobinopathathies) were observed (15,16).…”

Section: Discussionmentioning

confidence: 96%

Fetal hemoglobin and hemoglobin A1c level among pediatric patients with type 1 diabetes

Baranowska-Jaźwiecka¹,

Mianowska²,

Fendler³

et al. 2016

Pediatr Endocrino Diabetes Metab

View full text Add to dashboard Cite

show abstract

Evaluation of glycated hemoglobin and fetal hemoglobin-adjusted HbA1c measurements in infants

Cited by 17 publications

References 20 publications

Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes

Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes

Glycemic control indicators in patients with neonatal diabetes mellitus

Fetal hemoglobin and hemoglobin A1c level among pediatric patients with type 1 diabetes

Contact Info

Product

Resources

About